Regeneron/Sanofi Offer Free Praluent Samples To Counter Slow Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
Ten days post the US launch of closely-watched Praluent, Regeneron said it plans to distribute free samples of the drug in response to slow reimbursement decisions.
You may also be interested in...
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.